Targeted and Chemo-Free Approaches in HER2-Positive Early Breast Cancer
Chemotherapy-free regimens demonstrate promising responses and survival outcomes in patients with HER2-positive early breast cancer. However, the combination of anti-HER2 drugs with chemotherapy still demonstrates superior overall clinical outcomes.
Authors
- Dali Edwards
- Navkirat Kahlon
- Asma Taj (ORCID: https://orcid.org/0000-0003-2789-2603)
- Zaheer Qureshi (ORCID: https://orcid.org/0000-0002-8478-0547)
- Abdur Jamil
- Fatima Hameed
Institutions
- Medical University of South Carolina (US)
- Good Samaritan Medical Center (US)
- Bolton NHS Foundation Trust (GB)
- Wentworth Douglass Hospital (US)
- Quinnipiac University (US)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1097/coc.0000000000001285
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00